intranasal delivery comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-20. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
Solid material is normally kept at minus 20 degrees Celsius in a sealed, desiccated container. Reconstituted solutions are less stable and are usually divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of activity. Light exposure is minimized by using amber glassware or foil wrapping. Published stability data for this peptide are sparse, so recommended storage conditions rest mainly on general practice for short synthetic peptides rather than on dedicated study.
Identity and purity are commonly assessed by reversed-phase high-performance liquid chromatography, with ultraviolet detection near 214 nanometers for the peptide backbone. Mass spectrometry, either electrospray or matrix-assisted laser desorption, confirms molecular mass and detects truncation or modification products. Amino acid analysis can verify composition. Because the sequence contains no strongly absorbing aromatic residue apart from phenylalanine, detection wavelengths are chosen carefully. Purity values above 95 percent are typical for research-grade material.
=== Osteonecrosis of the jaw after use of Fosamax === Fosamax (alendronate) is a bisphosphonate used for the treatment of post-menopausal osteoporosis and for the prevention of skeletal problems in certain cancers. The American College of Clinical Endocrinology, the American College of Obstetricians and Gynecologists, the North American Menopause Society and the UK National Osteoporosis Guideline Group recommend alendronate and certain other bisphosphonates as first line treatments for post-menopausal osteopotosis. Long-term treatment with bisphosponates produces anti-fracture and bone mineral density effects that persist for 3–5 years after an initial 3–5 years of treatment. Alendronate reduces the risk of hip, vertebral, and wrist fractures by 35-39%. In December 2013, Merck agreed to pay a total of $27.7 million to 1,200 plaintiffs in a class action lawsuit alleging that the company's osteoporosis drug had caused them to develop osteonecrosis of the jaw. Prior to the settlement, Merck had prevailed in 3 of 5 so-called bellwether trials. Approximately 4,000 cases still await adjudication or settlement as of August 2014. There have also been thousands of lawsuits alleging that Fosamax increased the risk of thigh-bone fractures. In March 2022, Merck defeated approximately 500 lawsuits over Fosamax in New Jersey when U.S. District Judge Freda L. Wolfson ruled that the plaintiffs' lawsuit was preempted by federal law.
While there's not much of a relationship between this hormone and physical plant behavior, there are behavioral changes that go on inside the plant in response to it. Cytokinin defense effects can include the establishment and growth of microbes (delay leaf senescence), reconfiguration of secondary metabolism or even induce the production of new organs such as galls or nodules. These organs and their corresponding processes are all used to protect the plants against biotic/abiotic factors.
In order to maintain the cell membrane potential, cells keep a low concentration of sodium ions and high levels of potassium ions within the cell (intracellular). The sodium–potassium pump mechanism moves 3 sodium ions out and moves 2 potassium ions in, thus, in total, removing one positive charge carrier from the intracellular space (see § Mechanism for details). In addition, there is a short-circuit channel (i.e. a highly K-permeable ion channel) for potassium in the membrane, thus the voltage across the plasma membrane is close to the Nernst potential of potassium.
== Biological synthesis == Hyaluronic acid is synthesized by a class of integral membrane proteins called hyaluronan synthases, of which vertebrates have three types: HAS1, HAS2, and HAS3. These enzymes lengthen hyaluronan by repeatedly adding D-glucuronic acid and N-acetyl-D-glucosamine to the nascent polysaccharide as it is extruded via ABC-transporter through the cell membrane into the extracellular space. The term fasciacyte was coined to describe fibroblast-like cells that synthesize HA. Hyaluronic acid synthesis has been shown to be inhibited by 4-methylumbelliferone (hymecromone), a 7-hydroxy-4-methylcoumarin derivative. This selective inhibition (without inhibiting other glycosaminoglycans) may prove useful in preventing metastasis of malignant tumor cells. There is feedback inhibition of hyaluronan synthesis by low-molecular-weight hyaluronan (<500 kDa) at high concentrations, but there is stimulation by high-molecular-weight hyaluronan (>500 kDa) when tested in cultured human synovial fibroblasts. Bacillus subtilis recently has been genetically modified to culture a proprietary formula to yield hyaluronans, in a patented process producing human-grade product.
The genealogy of lifting can be traced back to the beginning of recorded history where humanity's fascination with physical abilities can be found among numerous ancient writings. In many prehistoric tribes, they would have a big rock they would try to lift, and the first one to lift it would inscribe their name into the stone. Such rocks have been found in Greek and Scottish castles. Progressive resistance training dates back at least to Ancient Greece, when legend has it that wrestler Milo of Croton trained by carrying a newborn calf on his back every day until it was fully grown. Another Greek, the physician Galen, described strength training exercises using the halteres (an early form of dumbbell) in the 2nd century. Ancient Greek sculptures also depict lifting feats. The weights were generally stones, but later gave way to dumbbells. The dumbbell was joined by the barbell in the later half of the 19th century. Early barbells had hollow globes that could be filled with sand or lead shot, but by the end of the century these were replaced by the plate-loading barbell commonly used today. Weightlifting was first introduced in the Olympics in the 1896 Athens Olympic Games as a part of track and field, and was officially recognized as its own event in 1914. The 1960s saw the gradual introduction of exercise machines into the still-rare strength training gyms of the time. Weight training became increasingly popular in the 1970s, following the release of the bodybuilding movie Pumping Iron, and the subsequent popularity of Arnold Schwarzenegger.
Sources: en.wikipedia.org
The Rhodesian Bush War, a guerrilla conflict between the government and two rival communist-backed black Rhodesian groups, began in earnest two years later, and after several attempts to end the war Smith concluded the Internal Settlement with non-militant nationalists in 1978. Under these terms the country was reconstituted under black rule as Zimbabwe Rhodesia in June 1979, but this new order was rejected by the guerrillas and the international community. The Bush War continued until Zimbabwe Rhodesia revoked its UDI as part of the Lancaster House Agreement in December 1979. Following a brief period of direct British rule, the country was granted internationally recognised independence under the name Zimbabwe in 1980.
=== Fat === Most of a camel's fat is stored in its hump, which can weigh up to 80 pounds (36.3 kg). This fat store allows it to go long periods of time without eating. If a camel continuously uses its fat stores without replenishing, the humps will eventually become flaccid in appearance. The hump also aids with heat regulation, as nearly all of its fat is stored in the hump, as opposed to even distribution throughout the body. During the day, the camel's hump stores heat, which is then dissipated through the camel's body at night, allowing for better retention of water compared to other thermoregulation methods.
==== Calcitonin gene-related peptide (CGRP) inhibitors ==== Atogepant (AGN-241689; Aquipta; MK-8031; Qulipta) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [131] Eptinezumab (ALD-403; Lu-AG09221; Vyepti) – monoclonal antibody against calcitonin gene-related peptide (CGRP) – migraine [132] Erenumab (Aimovig; AMG-334) – monoclonal antibody against calcitonin gene-related peptide receptor (CGRPR) – migraine [133] Fremanezumab (Ajovy; LBR-101; PF-04427429; PF-4427429; RN-307; TEV-48125) – monoclonal antibody against calcitonin gene-related peptide (CGRP) – migraine [134] Galcanezumab (Emgality; LY-2951742) – monoclonal antibody against calcitonin gene-related peptide (CGRP) – cluster headache, migraine [135] Rimegepant (BHV-3000; BMS-927711; Nurtec; Vydura) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [136] Ubrogepant (MK-1602; Ubrelvy) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [137] Zavegepant (BHV-3500; BMS-742413; PF-07930207; Vazegepant; Zavzpret) – calcitonin gene-related peptide receptor (CGRPR) antagonist – migraine [138]
The Indian Council of Historical Research (ICHR) is an autonomous body of the Ministry of Education, Government of India established by an Administrative Order. The body has provided financial assistance to historians and scholars through fellowships, grants, and symposia. The ICHR receives grants-in-aid from the Department of Higher Education, grants-in-aid from various Indian states, private donations, and the proceeds of revenues from the sale of publications of the ICHR. The ICHR is based in Delhi, with regional centres in Pune (Maharashtra), Bengaluru (Karnataka), and Guwahati (Assam). It was established on 27 March 1972. Its first chairman was the historian Ram Sharan Sharma. Historians who have served as members or functionaries of the ICHR include Irfan Habib, Tapan Raychaudhuri, and Barun De.
Sources: en.wikipedia.org
Union of Sovereign States: The treaty proposed to set up a Union of Sovereign and Equal States based on democracy and rule-of-law as successor to the Union of Soviet Socialist Republics. This new polity was envisioned as a voluntary association of sovereign republics with a common federal government. A member joins the Union either directly or as a part of other states, and relations between members when one of them is a part of another are regulated by treaties between them. Presidential Council: The treaty proposed the creation of a Presidential Council that would consist of the leaders of the republics and the president of the Union. This council would be responsible for making important decisions and coordinating policies at federal level. A Union Constitutional Court would be created to settle disputes over questions of the exercise of the powers of Union organs. The legislative power of the Union would be exercised by the USSR Supreme Soviet, which consists of two chambers: the Soviet of the Republics, elected by the population of the whole country, and the Soviet of the Union. Decentralization of Power: The treaty aimed to decentralize political power by granting greater autonomy to the Republics giving them general guarantees about the right to control their own resources and legislate including the right to freely secede from the Union. Division of Powers: The central government would handle issues of defence, foreign affairs, financial system, energy resources and overall coordination along with issuing its currency.
I mean, I'm happier than—I can't even express it!" A live performance of "Use This Gospel" with West and Sunday Service Choir came a few days later, ushering in a new era of Clipse live performances at music festivals and award shows. They appeared again on "Punch Bowl" by Nigo, from his album I Know Nigo! (2022). No Malice made a guest appearance (credited as Malice) on "I Pray for You" by Pusha T, from his fourth album, It's Almost Dry (2022). "Chains & Whips", the first song with Clipse as the primary artist since the reunion, was previewed on June 20, 2023. When asked about a potential new album in a live interview on November 16, 2023, Malice responded "Not at this time" with a smile. An upcoming album was confirmed in a story for magazine Greatest, published December 1, 2023.
Afamelanotide, sold under the brand name Scenesse, is a medication used to prevent phototoxicity and to reduce pain from light exposure for people with erythropoietic protoporphyria, a rare form of genetic sun sensitivity. Afamelanotide is a melanocortin 1 receptor (MC1 receptor) agonist and a synthetic peptide and analogue of α-melanocyte stimulating hormone. It is administered as subcutaneous implant. In the European Union, afamelanotide is indicated for the prevention of phototoxicity in adults with erythropoietic protoporphyria. In the United States, afamelanotide is indicated for increasing pain-free light exposure in adults with a history of reactions to light (phototoxicity) from erythropoietic protoporphyria.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.